Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

This study has been terminated.
(Primary endpoint (HSP) could not be analyzed with the specified method in the planned interim analysis; a method of increased sensitivity had to be established.)
Sponsor:
Information provided by (Responsible Party):
Christoph Aufricht, Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT01353638
First received: May 5, 2011
Last updated: September 9, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2012
  Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)